Innovative Drugs

Antibody drugs are precision-targeted biotherapeutic agents. Their core principle is to mimic the body's native immune antibodies, accurately recognizing and binding to diseased cells and pathogenic proteins in vivo. This precision sets them apart from conventional chemotherapeutic agents, which carry substantial side effects. Through four generations of technological iteration, antibody drugs have evolved from early mouse-derived antibodies—once prone to immune rejection—to safe and stable fully human antibodies, greatly reducing adverse immune reactions in patients. Major clinical antibody modalities today include monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and the emerging antibody-oligonucleotide conjugates (AOCs). They are widely applied in oncology, autoimmune disorders, cardiovascular diseases, ophthalmology, and the treatment of rare diseases. Conventional monoclonal antibodies exert therapeutic effects by blocking pathogenic signaling and activating the host immune system to eliminate lesions. ADCs combine the targeting specificity of antibodies with the cytotoxic potency of chemotherapeutic agents to achieve site-specific tumor therapy. Bispecific antibodies engage two distinct targets simultaneously to enhance therapeutic efficacy. As a next-generation conjugate modality following ADCs, AOCs fuse targeting antibodies with oligonucleotide-based gene therapeutics. They overcome the delivery limitations of conventional small-nucleic-acid drugs, enable precise modulation of disease-causing genes, and address unmet medical needs for extra-hepatic tissue lesions and rare genetic disorders. Featuring high target precision and durable therapeutic effects, antibody drugs are large-molecule biologic agents that can only be administered via injection. Their R&D and manufacturing processes are technically complex and relatively costly, making them cornerstone therapeutics in modern precision medicine.

Guided by national strategic imperatives and a commitment to original innovation, Sungen is dedicated to advancing antibody drug development to internationally leading standards. Sungen's mission is to build a differentiated product pipeline of First-in-Class and Best-in-Class candidates through front-end innovation. Backed by internationally advanced technology platforms — including the fully human antibody engineering platform, the X-Gen AI-powered drug discovery and antibody optimization platform, the antibody pilot-scale process development and manufacturing platform, the NexTreg™ technology platform, proprietary intellectual property-based ADC technology platform, and a comprehensive pharmacology and pharmacodynamics research platform — Sungen is advancing a robust portfolio of pioneering antibody drug candidates across cardiovascular and cerebrovascular diseases, oncology, autoimmune disorders, and other major therapeutic areas.